211 related articles for article (PubMed ID: 32990343)
1. Adjuvant therapy following oesophagectomy for adenocarcinoma in patients with a positive resection margin.
Bott RK; Beckmann K; Zylstra J; Wilkinson MJ; Knight WRC; Baker CR; Kelly M; Maisey N; Qureshi A; Sevitt T; Van Hemelrijck M; Smyth EC; Allum WH; Lagergren J; Gossage JA; Cunningham D; Davies AR;
Br J Surg; 2020 Dec; 107(13):1801-1810. PubMed ID: 32990343
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant therapy following neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma in patients with clear resection margins.
Bott RK; Beckmann K; Zylstra J; Wilkinson MJ; Knight WRC; Baker CR; Kelly M; Maisey N; Waters J; Van Hemelrijck M; Smyth EC; Allum WH; Lagergren J; Gossage JA; Cunningham D; Davies AR
Acta Oncol; 2021 May; 60(5):672-680. PubMed ID: 33586602
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant Chemotherapy vs Postoperative Observation Following Preoperative Chemoradiotherapy and Resection in Gastroesophageal Cancer: A Propensity Score-Matched Analysis.
Mokdad AA; Yopp AC; Polanco PM; Mansour JC; Reznik SI; Heitjan DF; Choti MA; Minter RR; Wang SC; Porembka MR
JAMA Oncol; 2018 Jan; 4(1):31-38. PubMed ID: 28975352
[TBL] [Abstract][Full Text] [Related]
4. The Role of Adjuvant Therapy in Patients With Margin-Positive (R1) Esophagectomy: A National Analysis.
Raman V; Jawitz OK; Voigt SL; Yang CJ; D'Amico TA; Harpole DH
J Surg Res; 2020 May; 249():82-90. PubMed ID: 31926400
[TBL] [Abstract][Full Text] [Related]
5. Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma.
Davies AR; Myoteri D; Zylstra J; Baker CR; Wulaningsih W; Van Hemelrijck M; Maisey N; Allum WH; Smyth E; Gossage JA; Lagergren J; Cunningham D; Green M;
Br J Surg; 2018 Nov; 105(12):1639-1649. PubMed ID: 30047556
[TBL] [Abstract][Full Text] [Related]
6. Prediction of a positive circumferential resection margin at surgery following neoadjuvant chemotherapy for adenocarcinoma of the oesophagus.
Knight WRC; Yip C; Wulaningsih W; Jacques A; Griffin N; Zylstra J; Van Hemelrijck M; Maisey N; Gaya A; Baker CR; Kelly M; Gossage JA; Lagergren J; Landau D; Goh V; Davies AR; ; Ngan S; Qureshi A; Deere H; Green M; Chang F; Mahadeva U; Gill-Barman B; George S; Dunn J; Zeki S; Meenan J; Hynes O; Tham G; Iezzi C
BJS Open; 2019 Dec; 3(6):767-776. PubMed ID: 31832583
[TBL] [Abstract][Full Text] [Related]
7. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
Luc G; Gronnier C; Lebreton G; Brigand C; Mabrut JY; Bail JP; Meunier B; Collet D; Mariette C
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1357-64. PubMed ID: 26014152
[TBL] [Abstract][Full Text] [Related]
8. The Role of Continuing Perioperative Chemotherapy Post Surgery in Patients with Esophageal or Gastroesophageal Junction Adenocarcinoma: a Multicenter Cohort Study.
Papaxoinis G; Kamposioras K; Weaver JMJ; Kordatou Z; Stamatopoulou S; Germetaki T; Nasralla M; Owen-Holt V; Anthoney A; Mansoor W
J Gastrointest Surg; 2019 Sep; 23(9):1729-1741. PubMed ID: 30671799
[TBL] [Abstract][Full Text] [Related]
9. Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma.
Noble F; Lloyd MA; Turkington R; Griffiths E; O'Donovan M; O'Neill JR; Mercer S; Parsons SL; Fitzgerald RC; Underwood TJ;
Br J Surg; 2017 Dec; 104(13):1816-1828. PubMed ID: 28944954
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study.
Kamarajah SK; Phillips AW; Ferri L; Hofstetter WL; Markar SR
Br J Surg; 2021 Apr; 108(4):403-411. PubMed ID: 33755097
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of the circumferential resection margin and its definitions in esophageal cancer patients after neoadjuvant chemoradiotherapy.
Depypere L; Moons J; Lerut T; De Hertogh G; Peters C; Sagaert X; Coosemans W; Van Veer H; Nafteux P
Dis Esophagus; 2018 Feb; 31(2):. PubMed ID: 29036407
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: significance of microscopically positive circumferential radial margins.
Harvin JA; Lahat G; Correa AM; Lee J; Maru D; Ajani J; Marom EM; Welsh J; Bhutani MS; Walsh G; Roth J; Mehran R; Vaporciyan A; Rice D; Swisher S; Hofstetter W
J Thorac Cardiovasc Surg; 2012 Feb; 143(2):412-20. PubMed ID: 22172216
[TBL] [Abstract][Full Text] [Related]
13. Prognosis after neoadjuvant chemoradiation or chemotherapy for locally advanced gastro-oesophageal junctional adenocarcinoma.
Vos EL; Carr RA; Hsu M; Nakauchi M; Nobel T; Russo A; Barbetta A; Tan KS; Tang L; Ilson D; Ku GY; Wu AJ; Janjigian YY; Yoon SS; Bains MS; Jones DR; Coit D; Molena D; Strong VE
Br J Surg; 2021 Nov; 108(11):1332-1340. PubMed ID: 34476473
[TBL] [Abstract][Full Text] [Related]
14. No Survival Difference with Neoadjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base.
Al-Sukhni E; Gabriel E; Attwood K; Kukar M; Nurkin SJ; Hochwald SN
J Am Coll Surg; 2016 Dec; 223(6):784-792.e1. PubMed ID: 27641320
[TBL] [Abstract][Full Text] [Related]
15. Complete clinical response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic oesophagus: is surgery always necessary?
Castoro C; Scarpa M; Cagol M; Alfieri R; Ruol A; Cavallin F; Michieletto S; Zanchettin G; Chiarion-Sileni V; Corti L; Ancona E
J Gastrointest Surg; 2013 Aug; 17(8):1375-81. PubMed ID: 23797888
[TBL] [Abstract][Full Text] [Related]
16. Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma.
Rice TW; Adelstein DJ; Chidel MA; Rybicki LA; DeCamp MM; Murthy SC; Blackstone EH
J Thorac Cardiovasc Surg; 2003 Nov; 126(5):1590-6. PubMed ID: 14666038
[TBL] [Abstract][Full Text] [Related]
17. Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer.
Tiesi G; Park W; Gunder M; Rubio G; Berger M; Ardalan B; Livingstone A; Franceschi D
J Surg Res; 2017 Aug; 216():65-72. PubMed ID: 28807215
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
19. Survival Benefit of Neoadjuvant Treatment in Clinical T3N0M0 Esophageal Cancer: Results From a Retrospective Multicenter European Study.
Mantziari S; Gronnier C; Renaud F; Duhamel A; Théreaux J; Brigand C; Carrère N; Lefevre JH; Pasquer A; Demartines N; Collet D; Meunier B; Mariette C;
Ann Surg; 2017 Nov; 266(5):805-813. PubMed ID: 28742698
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Chemotherapy Does Not Improve Recurrence-Free Survival in Patients With Stage 2 or Stage 3 Rectal Cancer After Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision.
Voss RK; Lin JC; Roper MT; Al-Temimi MH; Ruan JH; Tseng WH; Tam M; Sherman MJ; Klaristenfeld DD; Tomassi MJ
Dis Colon Rectum; 2020 Apr; 63(4):427-440. PubMed ID: 31996583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
